Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.

Andreas E KremerMarlyn J MayoGideon HirschfieldCynthia LevyChristopher L BowlusDavid E JonesAlexandra SteinbergCharles A McWherterYun-Jung Choi

Published in: Liver international : official journal of the International Association for the Study of the Liver (2021)

Seladelpar treatment for 1 year led to consistent improvement in both symptom burden and biochemical response, suggesting its potential as a single agent to address two key unmet needs in PBC patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
sleep quality
peritoneal dialysis
physical activity
prognostic factors
depressive symptoms
risk factors
combination therapy